LONDON – A UK start-up has unveiled plans to form a £39 million (US$62 million) cancer research center after reaching proof of principal for a technology, originally developed at AstraZeneca plc, which makes it possible to generate patentable analogues of existing drugs. (BioWorld International) Read More
